Published: Dec, 2017

Carglumic acid is an orphan drug that is used for treating patients suffering from hyperammonemia, a urea cycle disorder that is caused due to the lack of a certain enzyme in the liver. This also implies deficiency of N-acetylglutamate (NAG) synthase. Carglumic acid helps in detoxification and removal of ammonia from blood cells.

Carglumic acid is on the verge of becoming an indispensable tool for managing life-threating metabolic disorders that affect the urea cycle. Carglumic acid is also being used in enhancing ammonia detoxification in patients with organic acidurias. Recently, carglumic acid has also shown potential for anti-tumor activity in breast cancer. Carglumic acid activates caspase 3 which helps in promoting cell apoptosis and also suppress tumor growth. Meanwhile, new formulations are also being developed by leading pharmaceutical companies to effectively treat urea cycle disorders and also to strengthen their product portfolio. In order to prevent brain damage in children, researchers have also combined metabolomics analysis of carglumic acid with genome sequencing.

The report also offers a detailed profile of some of the leading players in the global market for carglumic acid such as Dipharma Francis S.r.l, Recordati S.p.A, and Civentichem, LLC.

carglumic acid market

Global Market for Carglumic Acid to Witness Robust Growth during the Forecast Period 2017-2026

According to a study by Transparency Market Research (TMR), the global market for carglumic acid is likely to witness strong growth. The market is projected to register 7.5% CAGR during the forecast period 2017-2026. It is also estimated to bring in US$ 187.0 million revenue by the end of 2026.

The global market for carglumic acid is segmented on the basis of distribution channel, delivery format, and region. On the basis of delivery format, the market segment includes Tablet, for suspension and Tablet, orally disintegrating. Among these, tablet, for suspension is likely to account for maximum revenue share in the global market for carglumic acid between 2017 and 2026.

On the basis of distribution channel, the market is segmented into Hospital Pharmacies. E-Commerce, and Retail Pharmacies. High sales is expected through hospital pharmacies during the forecast period 2017-2026.

North America to Account for the Highest Growth in the Global Carglumic Acid Market

Geographically, the market is segmented into Asia Pacific Excluding Japan (APEJ), Japan, Europe, North America, Latin America, and the Middle East and Africa (MEA). North America is likely to be one of the largest regions in the global market for carglumic acid market. Owing to the Increasing incidence of hyperammonemia in North America, carglumic acid is gaining popularity among the healthcare professionals in the region. Moreover, pharmaceutical companies and the regulatory bodies in the region are also focusing on creating an awareness about carglumic acid, along with its dosage and use. Meanwhile, Europe is also likely to witness significant growth in the global carglumic acid market in the near future. High prevalence of NAGS deficiency among the European population, especially among the newborns. Hence, the demand for effective treatment that can help in pulling high ammonium levels to normal is also increasing. Moreover, Orphan Europe, a leading company in orphan drugs in Europe has developed Carbaglu (carglumic acid). Carbaglu is also the first drug that has been approved by the Food and Drug Administration (FDA) for treating NAGS deficiency.  

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453